StockNews.AI

Vericel Announces Preliminary 2025 Financial Results and Business Updates

StockNews.AI • 7 hours

MEDPNVCRHOLX
High Materiality8/10

Information

Total Revenue Expected to be $276 Million  MACI Revenue Expected to be $239.5 Million Fourth Quarter...

Original source

AI Summary

VCEL projects $276 million total revenue for 2025. MACI revenue expected at $239.5 million, growing 20% or more annually. Gross margin anticipated at 74% with a net income forecast for GAAP. Company shows strong performance with rapid MACI utilization growth. VCEL to present at J.P. Morgan Healthcare Conference today.

Sentiment Rationale

Strong revenue growth and profitability are likely to boost investor confidence, similar to past bullish trends during high-growth periods.

Trading Thesis

The announcement likely affects VCEL's stock price quickly due to financial results and conference presentation.

Market-Moving

  • VCEL projects $276 million total revenue for 2025.
  • MACI revenue expected at $239.5 million, growing 20% or more annually.
  • Gross margin anticipated at 74% with a net income forecast for GAAP.

Key Facts

  • VCEL projects $276 million total revenue for 2025.
  • MACI revenue expected at $239.5 million, growing 20% or more annually.
  • Gross margin anticipated at 74% with a net income forecast for GAAP.
  • Company shows strong performance with rapid MACI utilization growth.
  • VCEL to present at J.P. Morgan Healthcare Conference today.

Companies Mentioned

  • MEDP (MEDP)
  • NVCR (NVCR)
  • HOLX (HOLX)

Corporate Developments

Positive financial results and growth potential are likely to attract investor interest, thereby impacting the stock price.

Vericel (VCEL) Announces Preliminary 2025 Financial Results and Business Updates

Date: January 13, 2026 | Source: GlobeNewsWire

Strong Revenue Performance in 2025

Vericel Corporation (NASDAQ:VCEL), a leader in sports medicine and severe burn care therapies, has reported preliminary unaudited financial results for the fourth quarter and full year ending December 31, 2025. The company anticipates total net revenue of approximately $276 million, with MACI® (autologous cultured chondrocytes on porcine collagen membrane) anticipated to contribute $239.5 million and Burn Care generating $36.5 million.

This performance marks a significant 23% growth in total revenue and MACI revenue in the fourth quarter compared to the prior year.

Financial Highlights for 2025

  • Gross Margin: Expected to be 74%
  • Adjusted EBITDA Margin: Anticipated at 26%
  • GAAP Net Income: Expected profitability for the second consecutive year
  • Cash and Investments: Approximately $200 million with no debt

Key Business Developments

Vericel achieved the highest number of MACI implants and implanting surgeons in any quarter since the product's launch in the fourth quarter of 2025. The company has also recorded MACI revenue growth of over 20% for three consecutive years.

Other highlights include:

  • Expansion of the MACI sales force
  • More than 900 MACI Arthro® trained surgeons by year-end 2025
  • Initiated the MACI Ankle™ MASCOT clinical study
  • Plans to commence MACI commercial manufacturing in a new facility in 2026

CEO Remarks on Company Momentum

Nick Colangelo, President and CEO of Vericel, remarked, “The Company executed extremely well in 2025, delivering strong revenue and profitability growth. We are entering 2026 with a great deal of momentum and expect another year of high revenue growth and increasing MACI utilization as we progress toward our mid-term financial targets.”

Upcoming Presentation and Investor Relations

Vericel is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. The presentation will be available via webcast in the Investor Relations section of the Vericel website at http://investors.vcel.com.

About Vericel Corporation

Vericel Corporation specializes in advanced therapies for sports medicine and severe burn care. The company's portfolio includes innovative cell therapies and specialty biologics. In the U.S., Vericel markets three primary products:

  • MACI®: For repairing knee cartilage defects
  • Epicel®: A permanent skin replacement for severe burns
  • NexoBrid®: For eschar removal in burn patients

Important Notices

The financial results disclosed herein are preliminary and unaudited, pending completion of internal reviews and audits. Actual results may differ significantly from current estimates.

Vericel’s financial measures include both GAAP and non-GAAP metrics to provide insight into the company's underlying performance. Investors are encouraged to consider these factors when evaluating the company's financial health.

Related News